Advancing Cancer Care: Predicting Mesothelioma Survival Time Using Deep Learning

ByHolly Zink
Advancing Cancer Care: Predicting Mesothelioma Survival Time Using Deep Learning

Cancer treatment is complex. Doctors need to estimate how long patients might live to choose the best treatments. New technologies like machine learning and deep learning have improved this process. These technologies are especially good at predicting how long cancer patients might survive.

Novel Approach

A new study focuses on a rare cancer called epithelioid malignant peritoneal mesothelioma. Researchers have developed a new deep learning network to predict how long patients with this cancer might live. This new approach is more efficient than others because it doesn’t require manual note-taking.

The new model was tested using clinical data. They included factors like the Peritoneal Cancer Index and whether patients received chemotherapy. The results showed that the model performed better than other methods. This was especially true when considering adjuvant chemotherapy. This suggests that adjuvant chemotherapy could significantly impact how long mesothelioma patients survive.

Other factors did not have as much influence on predicting survival times. These included neoadjuvant chemotherapy, Hyperthermic Intraperitoneal Chemotherapy (HIPEC), and demographic information.

This new deep learning model is a valuable tool for estimating survival times for mesothelioma patients. It has already shown the importance of considering adjuvant chemotherapy in predicting survival outcomes. This research provides valuable insights for doctors treating mesothelioma patients and shows the potential of deep learning in improving cancer survival analysis.

Source:

Papadopoulos, Kleanthis Marios, Panagiotis Barmpoutis, Tania Stathaki, Vahan Kepenekian, Peggy Dartigues, Séverine Valmary-Degano, Claire Illac-Vauquelin, et al. “Overall Survival Time Estimation for Epithelioid Peritoneal Mesothelioma Patients from Whole-Slide Images.” BioMedInformatics 4, no. 1 (March 2024): 823–36. https://doi.org/10.3390/biomedinformatics4010046.

Similar Posts

Inflammation Both “Friend and Foe” in Mesothelioma
| |

Inflammation Both “Friend and Foe” in Mesothelioma

ByAlex Strauss

An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

New Detection System for Mesothelioma
| |

New Detection System for Mesothelioma

ByAlex Strauss

A team of biotech scientists in New York have developed an electrochemical process they say can help clinicians detect mesothelioma cells in blood serum. The system works by detecting a protein (HAPLN1) known to be expressed at high levels in the blood serum of people with malignant pleural mesothelioma. Detecting mesothelioma as early as possible is of critical importance because mesothelioma is such a difficult cancer to treat. Associated with asbestos exposure, mesothelioma starts on the membrane around the lungs, heart, or abdomen. It typically grows quickly and does not respond to conventional treatments like chemotherapy or radiotherapy. Biomarkers like the HAPLN1 protein may be value if they can help clinicians distinguish mesothelioma from other conditions with similar symptoms. The scientists…

New Mesothelioma Test Available Later This Year
| |

New Mesothelioma Test Available Later This Year

ByAlex Strauss

A mesothelioma test created and validated at Brigham and Women/s Hospital in Boston could be available to the public within the next couple of months. The test, which will be known by the brand name DecisionDx-Mesothelioma, is designed to test patients who are suspected of having mesothelioma for the expression of a variety of genes. By creating a gene profile, the test can give doctors a clearer picture of which patients with mesothelioma symptoms might actually be suffering from the disease. Friendswood, Texas-based Castle Biosciences has announced that it has acquired the intellectual property and technology rights to the test from Brigham and Women’s. Castle Biosciences specializes in molecular diagnostic tests for rare cancers like mesothelioma. Currently, the company has three proprietary…

New Tools Help Pathologists Make Mesothelioma Diagnosis
| |

New Tools Help Pathologists Make Mesothelioma Diagnosis

ByAlex Strauss

Pathologists may be able to do a better job of diagnosing mesothelioma in the lab, thanks to a new set of tools released by the International Mesothelioma Interest Group. A rare malignancy, mesothelioma typically carries a poor prognosis. Part of the reason may be the difficulty of making an accurate diagnosis. Even with sophisticated testing capabilities, including immunohistochemical staining and electron microscopy, it can be difficult to distinguish mesothelioma from other types of cancer. Now, pathologists who work with the International Mesothelioma Interest Group have come up with a list of guidelines they hope will help streamline the process in laboratories around the world. Drawing on their own experiences, as well as studies in peer-reviewed publications and text books, the group came…

Ultrasound: A Safer Way to Manage Mesothelioma?
| |

Ultrasound: A Safer Way to Manage Mesothelioma?

ByAlex Strauss

The same technology used by obstetricians to track pregnancies and by cardiologists to find blood clots may also play a valuable role in managing mesothelioma. An Indonesian mesothelioma doctor says ultrasound technology is not only safer than radiation, but also portable, non-invasive and relatively inexpensive to use. In a recent article published in an Indonesian medical journal, Dr. C.M. Rumende of the University of Indonesia Medical School says ultrasonography of the lungs allows clinicians to diagnose some abnormalities common in mesothelioma, including the buildup of lung fluid known as pleural effusion, more rapidly than they could with other imaging modalities. “In addition to pleural effusion,” observes Dr. Rumende, “other lung disorders can be diagnosed by ultrasound such as peripheral lung tumors,…

Mesothelioma or Lung Cancer? Pleural Fluid May Tell
| |

Mesothelioma or Lung Cancer? Pleural Fluid May Tell

ByAlex Strauss

One of the biggest challenges in treating malignant pleural mesothelioma is making a definitive diagnosis. Mesothelioma is a cancer that occurs in the membranous tissue encasing the lungs and other organs. It is almost always caused by exposure to asbestos. Although mesothelioma is not technically a lung cancer, many of its most common symptoms, such as shortness of breath and coughing, are similar to lung cancer and other lung diseases. Like mesothelioma, many of these diseases cause a buildup of fluid around the lungs known as pleural effusion.  But there are subtle differences in the biochemical composition of that fluid from one disease to the next. A team of medical researchers in Japan is testing a new method for detecting and using…